ARTICLE | Clinical News

Saxenda Liraglutide 3 mg: Additional Phase IIIa data

November 10, 2014 8:00 AM UTC

Additional data from the double-blind, international Phase IIIa SCALE Obesity and Pre-diabetes trial in 3,731 patients without diabetes who are overweight or obese with co-morbidities such as pre-diabetes, hypertension and dyslipidemia showed that 92% of patients receiving once-daily 3 mg subcutaneous liraglutide had body weight loss at week 56 vs. 65% for placebo. Additionally, 3 mg subcutaneous liraglutide significantly increased the proportion of patients who achieved a reduction in weight from baseline to week 56 of >=5% (63% vs. 27%, p<0.0001), >10% (33% vs. 11%, p<0.0001) and >15% (14% vs. 3.5%, p<0.0001). Patients who completed 56 weeks of treatment with 3 mg subcutaneous liraglutide (n=1,789) lost 9.2% (9.7 kg) of their baseline bodyweight compared to 3.5% (3.8 kg) of baseline bodyweight in patients who completed placebo treatment (n=801) (p<0.0001). Bodyweight loss was similar in patients with pre-diabetes at screening vs. those without (8% vs. 7.9%, p=0.59). Data were presented at ObesityWeek meeting in Boston. In 2013, Novo Nordisk reported that 3 mg subcutaneous liraglutide met the 3 co-primary endpoints vs. placebo (see BioCentury, May 27, 2013). ...